Pfizer has been busy creating new antiviral therapies for COVID-19. In fact, earlier this year, TrialSite reported on an antiviral pill going to trial. Just recently, we announced Pfizer’s move to secure emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA). Russia, in general, continues to struggle more than most countries during this ongoing pandemic. Now, Pfizer will take their antiviral called Paxlovid and conduct studies in Russia, a state registry of medicines showed on Tuesday. While Russians have access to forms of Favipiravir, this antiviral only shows limited benefit. Russians experience significant vaccine hesitancy as well, as only about 36% of the nation’s population are fully vaccinated.
The trials conducted on 90 people located in home-like conditions with someone who has symptomatic COVID-19 began on Nov. 12 and will continue until March 2023, the registry's website said.
Pfizer said earlier this month the experimental antiviral pill cut by 89% the chance of hospitalization or death for adults at risk of severe disease. It hopes to make the pill available globally as quickly as possible.
Pfizer's pill, with the brand name Paxlo...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).